GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according ...